Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
Public ClinicalTrials.gov record NCT05387837. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 3 Stage Ph 2 Study: St 1: Single SubQ D-4517.2 Dose Safety and PD in Wet wAMD or DME. Stage 1A: Multiple SubQ D-4517.2 Dose Safety, PK and PD in wAMD and DME. Stage 2: Safety, Tolerability, PK and Efficacy of SubQ D-4517.2 in wAMD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)
Study identification
- NCT ID
- NCT05387837
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 50 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2022 (Actual)
- Primary completion
- May 9, 2025 (Estimated)
- Completion
- Sep 30, 2025 (Estimated)
- Last update posted
- May 4, 2025
2022 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Macro Trials | Los Angeles | California | 90026 | — |
| University Retina - Lemont | Lemont | Illinois | 60439 | — |
| Midwest Eye Institute - North | Indianapolis | Indiana | 46290 | — |
| Cumberland Valley Retina Consultants | Hagerstown | Maryland | 21740 | — |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02114 | — |
| Springield Clinic | Springfield | Missouri | 62794 | — |
| The Retina Institute - Clayton Office | St Louis | Missouri | 63128 | — |
| Envision Ocular, LLC | Bloomfield | New Jersey | 07003 | — |
| Erie Retina Research | Eire | Pennsylvania | 16507 | — |
| Texas Retina Associates - Arlington | Arlington | Texas | 76012 | — |
| Austin Retina Associates | Austin | Texas | 78705 | — |
| Medical Center Ophthalmology Associates - Northwest | San Antonio | Texas | 78240 | — |
| Retinal Consultants of San Antonio | San Antonio | Texas | 78240 | — |
| Strategic Clinical Research Group | Willow Park | Texas | 76087 | — |
| Virginia Retina Center | Leesburg | Virginia | 20176 | — |
| West Virginia University Eye Institute | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05387837, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05387837 live on ClinicalTrials.gov.